Kirk Campbell, MD
img_Kirk Campbell
PROFESSOR | Medicine, Nephrology
PROFESSOR | Pharmacological Sciences
Are you a patient?
Multi-Disciplinary Training Area
Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression. Please go to The Campbell Laboratory at

MD, University of Connecticut School of Medicine

Residency, Internal Medicine, Yale New Haven Hospital

Fellowship, Nephrology, Mount Sinai Hospital

FSGS Grand Rounds
Kirk Campbell, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Campbell during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Access for Life
  • National Kidney Foundation
  • Reata Pharmaceuticals
  • Vertex Pharmaceuticals Incorporated
  • Travere (Formerly Retrophin)
  • Calliditas Pharmaceuticals
  • Goldfinch Bio
  • Chinook Therapeutics

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose

  • Medscape

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.